Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.48 |
| ▸ | HK1 | P19367 | 1/20 | 0.48 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.48 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.31 |
| ▸ | TAS2R46 | P59540 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17195889 | 0.87 | NSD2 (0.46) | NSD2HK1HKDC1 | |
| SCHEMBL6705482 | 0.82 | KDM4E (0.31) | NSD2HK1HKDC1 | |
| SCHEMBL17122004 | 0.81 | NSD2 (0.33) | NSD2HK1HKDC1 | |
| SCHEMBL10593202 | 0.78 | — | — | |
| SCHEMBL10633275 | 0.77 | NSD2 (0.49) | NSD2HK1HKDC1 | |
| SCHEMBL10903809 | 0.77 | NSD2 (0.49) | NSD2HK1HKDC1 | |
| SCHEMBL6703741 | 0.72 | PPARG (0.31) | — | |
| SCHEMBL11019899 | 0.72 | NSD2 (0.54) | NSD2HK1HKDC1 | |
| SCHEMBL11832717 | 0.72 | NSD2 (0.70) | NSD2HK1HKDC1 | |
| SCHEMBL4352284 | 0.72 | KMT2A (0.41) | FNTAPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708413-B2 | Glycosylated linker, compound containing glycosylated linker moiety and physiologically active substance moiety or salt thereof, and methods for producing said compound or salt thereof | GLYTECH, INC. (JP) | 2017-07-18 | — | — | US | disclosed |
| US-20150299337-A1 | GLYCOSYLATED LINKER, COMPOUND CONTAINING GLYCOSYLATED LINKER MOIETY AND PHYSIOLOGICALLY ACTIVE SUBSTANCE MOIETY OR SALT THEREOF, AND METHODS FOR PRODUCING SAID U OR SALT THEREOF | GLYTECH INC (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20050228180-A1 | Alpha, omega-dicarboximide derivatives as useful uro-selective a1a adrenoceptor blockers | RANBAXY LABORATORIES LIMITED (IN) | 2005-10-13 | — | — | US | disclosed |
| EP-1495000-A4 | ALPHA, OMEGA-DICARBOXIMIDE DERIVATIVES AS USEFUL URO-SELECTIVE A1A ADRENOCEPTOR BLOCKERS | RANBAXY LAB LTD (IN) | 2005-10-05 | — | — | EP | disclosed |
| EP-1495000-A1 | ALPHA, OMEGA-DICARBOXIMIDE DERIVATIVES AS USEFUL URO-SELECTIVE A1A ADRENOCEPTOR BLOCKERS | RANBAXY LABORATORIES, LTD. (IN) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003084928-A1 | ALPHA, OMEGA-DICARBOXIMIDE DERIVATIVES AS USEFUL URO-SELECTIVE Α1Α ADRENOCEPTOR BLOCKERS | RANBAXY LABORATORIES LIMITED (IN) | 2003-10-16 | — | — | WO | disclosed |
| US-4043930-A | PREVENTION OF SCALE FORMATION | JOH. A. BENCKISER GMBH (DT) | 1977-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299337-A1 | GLYCOSYLATED LINKER, COMPOUND CONTAINING GLYCOSYLATED LINKER MOIETY AND PHYSIOLOGICALLY ACTIVE SUBSTANCE MOIETY OR SALT THEREOF, AND METHODS FOR PRODUCING SAID U OR SALT THEREOF | CD44, CSGALNACT1, UGGT1 | NSD2 4078/4885HK1 740/4885HKDC1 699/4885 |
| US-20050228180-A1 | Alpha, omega-dicarboximide derivatives as useful uro-selective a1a adrenoceptor blockers | ADRA1A, ADRB1, ADRA1B | NSD2 4563/4885HK1 2237/4885HKDC1 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.